

Osta Biotechnologies Inc.  
Press Release  
For Immediate Distribution

## **OSTA BIOTECHNOLOGIES ANNUAL AND SPECIAL MEETING**

June 20, 2007 — **Osta Biotechnologies Inc.** (TSX Venture Exchange: OBI) is pleased to announce that at the annual and special meeting of shareholders of Osta Biotechnologies Inc. held on June 18, 2007, Osta's shareholders elected a Board of Directors consisting of Dr. Ajay Gupta, Dr. Andrew Karaplis, Dr. Aldo Baumgartner, Paul L'Archevêque, Richard Spizzirri and Leontis Teryazos. Dr. Gupta is the Chairman and Chief Executive Officer of Osta, Dr. Karaplis is the President and Mr. William Waks, CA is the Chief Financial Officer. The shareholders also re-appointed WSBG LLP, Chartered Accountants, as auditors of the corporation.

Osta expresses its thanks to Messrs. James H. Coleman and James W. Beckerleg, who have left the Osta Board of Directors. Messrs. Coleman and Beckerleg, served as directors of Osta since 2004. Osta also expresses its thanks to Mr. Joel Cohen, who stepped down as Chief Financial Officer of Osta, but who continues to serve the corporation in an advisory capacity.

At the meeting, the shareholders also approved, subject to regulatory approval, including that of the TSX Venture Exchange, an amendment to the Stock Option Plan of the Corporation so as to increase the maximum number of common shares reserved for issuance upon the grant of options from 4,000,000 to 5,000,000, as described in Osta's proxy circular dated May 18, 2007.

Osta also announces that at a Board of Directors meeting held after the annual and special meeting of shareholders, the Board of Directors approved the grant of an aggregate of 150,000 options to the independent directors. The options are exercisable at a price of \$0.28 per share for a period of five years, subject to the vesting provisions of the Stock Option Plan.

### **About Osta Biotechnologies Inc.**

Osta is a biopharmaceutical company listed on the TSX Venture Exchange dedicated to developing novel diagnostics and therapeutics for the aging population, particularly in the areas of Alzheimer's disease, Osteoporosis, Cancer and X-Linked Hypophosphatemic rickets (XLH).

For further information, please contact:

Osta Biotechnologies Inc.  
Mr. Alain Geahchan  
Director of Operations  
(514) 567-5505

Osta Biotechnologies Inc.  
Dr. Ajay Gupta  
Chairman & CEO  
(514) 626-0322

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy for this release.

*Certain information in this press release is forward-looking and is subject to numerous risks and uncertainties. By their nature, such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. These risks include actions of Osta's competitors, and those inherent in scientific research and development.*

*The issue of this press release is limited to Canada only. This press release should not be issued in the United States through U.S. news wire agencies.*